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Objective: To detect an early stage of pulmonary arterial hyperten-
sion (PAH) in patients with connective tissue diseases (CTD) who do
not show the signiﬁcant rise of tricuspid valve pressure gradient (TRPG)
by echocardiography in rest, using the exercise echocardiography.
Patients and methods: 27 patients with systemic sclerosis (SSc), 13
patients with mixed connective tissue disease (MCTD), 8 patients with
systemic lupus erythematosus (SLE), and 30 healthy controls (HC). To
these patients, exercise echocardiographywas performed. CTD patients
whose TRPG in rest was 31 mmHg or less were enrolled for this study
from September 2010 to June 2012. The patients included were when
TRPG on exercise went up by 35 mmHg or more from that in rest, right
heart catheterization (RHC) was conducted, if the patient's written
informed consent was obtained. Result: The average increase of TRPG
caused by exercise (delta TRPG) in SSc patients was higher than that in
SLE patients and HC (both p b 0.05). Although, there was no SLE
patients whose delta TRPG was 35 mmHg or more, 5 SSc patients and 3
MCTD patients showed 35 mmHg or more delta TRPG. Among these 8
patients, RHC was carried out for two SSc patients and two MCTD
patients who have agreed with implementation of RHC. Three patients
out of four were diagnosed as PAH by RHC. Conclusion: In CTD patients,
exercise echocardiography is a useful tool to detect early stage of PAH
patients who do not show the signiﬁcant rise of TRPG in rest.
doi:10.1016/j.lfs.2013.12.165
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In pulmonary arterial hypertension (PAH), increases in endothelin-1
(ET-1) contribute to elevated pulmonary vascular resistance which
ultimately causes death by right ventricular heart failure. ET antagonists
are effective in treating PAH but in marked contrast, lack efﬁcacy in
treating left ventricular heart failure. The aim of the study was to use
radioligand binding assays to quantify the density of ETA and ETB in
humanheart frompatientswith PAH and in an establishedmodel of PAH,
the monocrotaline (MCT) rat. This model recapitulates some of the
pathophysiological features of the human condition, including increase in
right ventricle systolic pressure and hypertophy. In the right ventricles of
PAH hearts, there was a signiﬁcant increase in the ratio of ETA receptors
(n= 12) but a decrease in ETB ratio comparedwith normal hearts. There
was no change in ratio in the left ventricle. In the MCT rat (n= 8),
receptor density was also signiﬁcantly different in the right ventricle
compared with vehicle control but with ETA downregulation and ETB
upregulation. There was no change in the left ventricle. In both human
PAH and MCT model, ET receptor density changes in the right ventricle
although the ratio was reversed in the rat. We have previously shown
that ETA receptors in the failing left ventricle of patients with ischaemic
heart disease are also signiﬁcantly increased. Endothelin is a potent
positive inotropic agent. In heat failure, increased receptor density may
be an adaptive response to increase beneﬁcial cardiac contractility. In
PAH, the main beneﬁt of ET antagonists may be in blocking deleterious
vascular effects rather than improving cardiac function.
doi:10.1016/j.lfs.2013.12.166
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Background: We previously reported that addition of bosentan in
pulmonary arterial hypertension (PAH) patients treatedwith high-dose
intravenous prostaglandin I2 (PGI2) decreased not only pulmonary
artery pressure but also reduced the dosage of PGI2. IP receptor, a PGI2
receptor, plays an important role in the treatment of PGI2. However the
relation of IP receptor and endotholin-1 is unknown. Methods: Effects
of PGI2 and endothelin-1 on IP receptor expression was examined by
qRT-PCR in pulmonary artery smooth muscle cells (PASMCs) obtained
from six patients with PAH. Results: PGI2 induced time and dose-
related down-regulation of IP receptor expression in PAH-PASMCs.
Endothelin-1 induced dose-related down-regulation of IP receptor
expression in PAH-PASMCs (Figure). Conclusion: Endothelin-1 down-
regulated the IP receptor in PAH-PASMCs.
doi:10.1016/j.lfs.2013.12.167
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Background: The efﬁcacy of oral triple upfront combination
therapy for severe idiopathic /heritable pulmonary arterial hyperten-
sion (I/HPAH) in long-term has not been established. Patients &
methods: We retrospectively reviewed three patients in WHO-FC III
who received oral triple upfront combination therapy (oral long-acting
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